Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q

Oncogene

Volumn 26, Issue 34, 2007, Pages 5010-5016

  Tews, B ^a   Roerig, P ^b   Hartmann, C ^c   Hahn, M ^a   Felsberg, J ^b   Blaschke, B ^b   Sabel, M ^b   Kunitz, A ^c   Toedt, G ^a   Neben, K ^a   Benner, A ^a   Deimling, A Von ^c   Reifenberger, G ^b   Lichter, P ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CITED4; CpG island; Gene expression profiling; Hypermethylation; Oligodendroglioma; Tumour suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CBP P300 INTEATING TRANSACTIVATOR WITH GLUTAMIC ACID ASPARTIC ACID RICH CARBOXY TERMINAL DOMAIN 4 PROTEIN; GENE PRODUCT; PROTEIN CITED4; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; TRANSCRIPTION REGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHILD; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE SILENCING; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; POLYMORPHISM, GENETIC; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 34547402002     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210297     Document Type: Article

References (25)

1. Alaminos M, Davalos V, Ropero S, Setien F, Paz MF, Herranz M et al. (2005). EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res 65: 2565-2571.
2. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. (2005). Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 11: 1119-1128.
3. Braganca J, Swingler T, Marques FI, Jones T, Eloranta JJ, Hurst HC et al. (2002). Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a coactivator for transcription factor AP-2. J Biol Chem 277: 8559-8565.
4. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al. (2006). Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24: 2707-2714.
5. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al. (1998). Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479.
6. Dong S, Pang JC, Hu J, Zhou LF, Ng H. (2002). Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer 98: 370-375.
7. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B et al. (2004). Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14: 121-130.
8. Fox SB, Braganca J, Turley H, Campo L, Han C, Gatter KC et al. (2004). CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. Cancer Res 64: 6075-6081.
9. Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD et al. (2006). Identification of der(1;19) (q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65: 988-994.
10. Grossman SR. (2001). p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem 268: 2773-2778.
11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
12. Iyer NG, Ozdag H, Caldas C. (2004). p300/CBP and cancer. Oncogene 23: 4225-4231.
13. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M et al. (2006). A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66: 9852-9861.
14. McDonald JM, Dunmire V, Taylor E, Sawaya R, Bruner J, Fuller GN et al. (2005). Attenuated expression of DFFB is a hallmark of oligodendrogliomas with 1p-allelic loss. Mol Cancer 4: 35.
15. McDonald JM, Dunlap S, Cogdell D, Dunmire V, Wei Q, Starzinski-Powitz A et al. (2006). The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. Cancer Biol Ther 5: 300-304.
16. Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. (2005). Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113: 379-385.
17. R Development Core Team (2005). A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, ISBN 3-900051-07-0, http://www.R-project.org.
18. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP. (2000). Oligodendroglial tumours and mixed gliomas. In: Kleihues P, Cavence WK (eds). Tumours of the Nervous System - Pathology and Genetics. World Health Organisation Classification of Tumours. IARC Press: Lyon, pp 55-70.
19. Reifenberger G, Louis DN. (2003). Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62: 111-126.
20. Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, Toedt G et al. (2006). Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer 119: 792-800.
21. Tibshirani R, Hastie T, Narasimhan B, Chu G. (2002). Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99: 6567-6572.
22. Tusher VG, Tibshirani R, Chu G. (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121.
23. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ et al. (2006). Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 20: 2715-2722.
24. van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS et al. (2003). Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 163: 1033-1043.
25. Wolf RM, Draghi N, Liang X, Dai C, Uhrbom L, Eklof C et al. (2003). p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Genes Dev 17: 476-487.